Endolaser retinopexy was associated with significantly higher anatomical success than cryotherapy, with combined treatment yielding intermediate outcomes in PPV for inferior RRD, and no significant association was observed between anatomical outcome and tamponade choice or PFCL use.
Abstract
Purpose
To evaluate associations between retinopexy modality, surgical and anatomical factors, and single-surgery anatomical success (SSAS) after pars plana vitrectomy (PPV) for primary inferior rhegmatogenous retinal detachment (RRD).
Methods
This retrospective single-center cohort included consecutive eyes undergoing PPV for primary inferior RRD with at least 3 months of follow-up. The primary outcome was SSAS, defined as absence of redetachment during follow-up and at least 2 months after silicone oil removal when applicable.
Results
Among 235 eyes, median follow-up was 8 months. SSAS was achieved in 175 eyes (74.5%), while 60 eyes (25.5%) redetached at a median of 35 days. SSAS was 83.3% with endolaser, 74.6% with combined retinopexy, and 64.6% with cryotherapy (p = 0.021). In multivariable analysis, endolaser was associated with lower odds of failure compared with cryotherapy (OR 0.21, 95% CI 0.09-0.48; p = 0.00037), while combined retinopexy was associated with intermediate odds of failure (OR 0.39, 95% CI 0.15-0.95; p = 0.043). Compared with PVR grade A, grade B (OR 5.19, 95% CI 2.30-12.37; p = 0.00011) and grade C (OR 10.60, 95% CI 4.15-28.84; p < 0.00001) were associated with higher odds of anatomical failure. A causative break at 6 o'clock was also associated with higher odds of failure (OR 4.61; p = 0.005).
Conclusion
In PPV for inferior RRD, endolaser retinopexy was associated with significantly higher anatomical success than cryotherapy, with combined treatment yielding intermediate outcomes. No significant association was observed between anatomical outcome and tamponade choice or PFCL use.
PURPOSE
To compare the anatomical and functional outcomes of pars plana vitrectomy (PPV) for primary uncomplicated rhegmatogenous retinal detachment (RRD) with superior versus inferior retinal breaks.
METHODS
This retrospective study included 675 eyes of 675 patients, of which 476 had exclusively superior breaks and...
Ioanna Dimakopoulou, M. Georgopoulos, Philipp Toubia Scholz et al.· Acta ophthalmologica· 0 citations
Adjunctive intravitreal methotrexate markedly improves morphological and functional outcomes in PVR-associated RRD, resulting in higher single-surgery success rates, reduced need for reoperation, and fewer postoperative sequelae.
Ehab Mohamed Elsayed Saad, Hazem Elbadry Mohammed Mohammed, S. A. Dabour et al.· Graefe's archive for clinica...· 0 citations
Purpose: The purpose of this study is to evaluate anatomical, visual, and safety outcomes after repeat pars plana vitrectomy combined with 360° encircling scleral buckling for first recurrent rhegmatogenous retinal detachment following primary vitrectomy. Methods: This retrospective single-centre cohort included 47 eye...
G. Panos, Alex Stubbing-Moore, D. Kumudhan et al.· Journal of Clinical Medicine· 0 citations
Vitrectomy combined with perifoveal centrifugal massage was associated with favorable anatomical and functional recovery in stage 4 EIFL-ERM, and this adjunctive technique may facilitate earlier stage regression and represents a potential refinement to standard iERM surgery.
L. Karabas, E. O. Tokuc, G. Kilic et al.· Retinal cases & brief report...· 0 citations
PURPOSE
To compare 6-month single-surgery anatomic success (SSAS) in eyes with giant retinal tear (GRT)-related retinal detachment (RD) treated with pars plana vitrectomy (PPV) with or without scleral buckle (SB), and to assess whether prophylactic fellow eye treatment reduces long-term GRT or RD risk.
METHODS
Retros...
LSV preserves letter-reading vision in about half of stage 4A eyes and in one of every six stage 4B eyes, and in one of every six stage 4B eyes with reattached retina does not guarantee measurable acuity.
I. Muftuoglu, K. Drenser, E. Nudleman et al.· Retina· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.